The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•18 April 2026•

1 min read

Omada Health Study Shows Enhanced Weight Loss Quality for GLP-1 Users

Key Facts

1Omada members on GLP-1s lost 1.8 times more total weight compared to the control group.

2The program reduced body fat percentage twice as much while increasing muscle mass percentage.

Omada Health (OMDA) has released clinical study results demonstrating that its GLP-1 Care Track program significantly enhances weight loss quality. The 12-week study, which followed 245 adults with obesity, found that members using the program lost 1.8 times more total weight compared to the control group. Notably, the program doubled the reduction in body fat percentage while successfully increasing the percentage of lean muscle mass. This clinical focus addresses a major industry concern regarding the loss of muscle mass, which can reach 40% during rapid weight loss with medications like semaglutide. These positive findings validate Omada's 'wraparound' care model, potentially increasing its competitive edge among enterprise clients and insurers in the high-growth GLP-1 market.